Provided by Tiger Fintech (Singapore) Pte. Ltd.

Repare Therapeutics Inc.

1.36
+0.03002.26%
Post-market: 1.360.00000.00%18:21 EDT
Volume:202.34K
Turnover:276.66K
Market Cap:57.81M
PE:-0.68
High:1.42
Open:1.33
Low:1.32
Close:1.33
Loading ...

Repare Therapeutics Seeks Partner Before Advancing Cancer Treatment

Dow Jones
·
10 Jan

Repare Therapeutics realigning resources to extend runway to mid-2027

TIPRANKS
·
10 Jan

Repare Therapeutics to seek partnering opportunities across portfolio

TIPRANKS
·
10 Jan

Repare Therapeutics announces portfolio reprioritization, partnering initiatives

TIPRANKS
·
10 Jan

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

THOMSON REUTERS
·
10 Jan

Repare Therapeutics Inc - Cost and Headcount Reductions to Extend Cash Runway to Mid-2027

THOMSON REUTERS
·
10 Jan

Repare Therapeutics Inc : Piper Sandler Cuts Target Price to $6 From $25

THOMSON REUTERS
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX) and Centene (CNC)

TIPRANKS
·
15 Dec 2024

Hold Rating on Repare Therapeutics Amid Mixed Trial Results and Anemia Concerns

TIPRANKS
·
14 Dec 2024

Repare Therapeutics Cut to Market Perform From Outperform by LifeSci Capital

Dow Jones
·
14 Dec 2024

Top Midday Decliners

MT Newswires Live
·
14 Dec 2024

Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results

GuruFocus.com
·
14 Dec 2024

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Eye Third Rate Cut

MT Newswires Live
·
13 Dec 2024

Investors Look to End Week on Strong Note as US Futures Rise in Friday's Premarket

MT Newswires Live
·
13 Dec 2024

LifeSci Capital downgrades Repare Therapeutics (RPTX) to a Hold

TIPRANKS
·
13 Dec 2024

Repare Therapeutics downgraded to Market Perform from Outperform at LifeSci Capital

TIPRANKS
·
13 Dec 2024

Repare Therapeutics Shares Fall as Phase 1 Trial Results for Cancer Drugs Disappoint Investors

MT Newswires Live
·
13 Dec 2024

Repare Therapeutics Shows Promise in Cancer Drug Trials

TIPRANKS
·
13 Dec 2024

Repare Therapeutics reports ‘positive’ results from MYTHIC Phase 1 trial

TIPRANKS
·
13 Dec 2024

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination From the Mythic Phase 1 Gynecologic Expansion Clinical Trial

THOMSON REUTERS
·
13 Dec 2024